马来酸曲美布汀:肠易激综合征治疗的另一选择

Trimebutine: Another Therapeutic Choice for Irritable Bowel Syndrome

背景:目前临床上肠易激综合征（IBS）的治疗有时较困难。目的:评价马来酸曲美布汀治疗IBS的疗效和安全性。方法:采用多中心、开放性试验,予符合要求的患者口服马来酸曲美布汀6周。治疗前后分别记录症状并检查血、尿、粪常规和肝、肾功能。结果:48例患者用药6周后的总改善率为78.8％,IBS的主要症状,如腹痛、腹胀都得到明显改善,有效率分别为95.7％和82.6％。未发生严重不良事件,共有5例次（10.2％）不良反应。结论:马来酸曲美布汀治疗IBS安全有效。

Background: The clinical therapy for irritable bowel syndrome (IBS) is sometimes difficult. Aims: To evaluate the efficacy and safety of trimebutine on the treatment of IBS. Methods: An open and multicenter study was carried out in Shanghai. In accordance with the inclusion and exclusion criteria, trimebutine was given to the patients orally for 6 weeks. The symptoms of IBS were recorded, and the blood, urine, stool, liver function and renal function were examined before and after the treatment. Results: After a 6-week course treatment, 78.8% of 48 patients were improved. The major symptoms of IBS were abdominal pain and distention, which were ameliorated markedly in 95.7% and 82.6% of patients, respectively. No serious side effect was found, the rate of side effect was 10.2% (5/49). Conclusions: Trimebutine is effective and safe in the treatment of IBS.